Expanding the technology toolbox
Our technology platforms enable our R&D teams to build on their deep knowledge and expertise across therapeutic modalities and scientific domains. From artificial intelligence (AI) to an expanded genetic alphabet, these tools are helping us drive progress at every stage of R&D.
Partnering for the future
We’re looking for well-matched partners whose novel approaches complement our expertise.
Together, we can discover, develop, and manufacture new medicines more quickly and with more precision than ever before.
Partnering success stories
Exscientia
We’re collaborating with Excientia on an end-to-end AI platform for drug discovery and translational research. It’s changing the way we make drugs for cancer and immune-mediated diseases.
Together, we aim to generate up to 15 novel small-molecule development candidates by discovering targets, accelerating research, and designing precision-engineered medicines.
Owkin
We’re partnering with Owkin to identify new drug targets and combinations and provide high-value insights through access to domain expertise and multimodal-trained AI.
We work on disease models that leverage our genomics and genetic datasets and provide access to research-grade cohorts that include longitudinal molecular, imaging, pathology, and outcome data.
IGM Biosciences
IGM Biosciences’s proprietary IgM antibody technology platform is helping us discover agonists against several targets.
Thanks to our exclusive, worldwide collaboration agreement, we can create, develop, manufacture, and commercialize IgM antibody agonists against several oncology and immunology targets.
Your partnering leads in Technology Platforms
For more information, contact us at TechnologyBD@sanofi.com
Brian Bronk
Global Head of Business Development, Neurology, Rare Diseases & Technology Platforms
Sarah Tao
Head of External Innovation, Technology Platforms